CFD's zijn complexe instrumenten en gaan gepaard met een hoog risico snel kapitaal te verliezen als gevolg van hefboommechanismen. 77.3% an de retailbeleggers lijdt verlies op de handel in CFD's met deze aanbieder. U dient zorgvuldig te overwegen of u begrijpt hoe CFD's werken en of u het zich kunt veroorloven om hoge risico's te nemen op het verliezen van uw kapitaal.

Close

Handelen Gilead GILD

Verkoop
 Koop

Gilead live grafieken

5m 15m 30m 1h 4h 1d 1w

instrument_fundamentals

Weekly Search
Weekly
Daily
Datum Sluit Verandering % verandering Openen Piek Bodem

Laatste marktnieuws

Frances Wang 2025 Apr 09, 16:00

Stock indices today: Nikkei 225 Rebounds After Yen Weakens Against Dollar

Indices
Tommy Yap 2025 Apr 09, 16:00

Morning Note: Trump Tariff U-Turn, US Inflation Awaited, Japan PPI Up

Morning Note
Frances Wang 2025 Apr 08, 16:00

GME Stock Price: what’s the risks and challenges ahead of GME stock?

Stocks
Tommy Yap 2025 Apr 08, 16:00

Morning Note: RBNZ Rate Cut, Oil Slide, Musk's Tariff Clash

Morning Note Oil
Frances Wang 2025 Apr 07, 16:00

Stock Market Today: Dow, S&P 500 Drop, Nasdaq Rises in Volatile Session

Indices Stocks
Tommy Yap 2025 Apr 07, 16:00

Morning Note: Trade Fears Hit Nvidia, Deepen US-China Clash; UK Seeks US Deal

Morning Note USD China
Frances Wang 2025 Apr 06, 16:00

Monthly Economic Report: Insights into Growth and Trends

Fed
Tommy Yap 2025 Apr 06, 16:00

Morning Note: Markets Tumble on Tariffs, Bitcoin Below $80K & Yen Gains

Morning Note Cryptocurrencies Forex

Info

Spread

0.63

Spread (%)

0.6240 %

Hefboom

1:5

Dagrente kopen

-0.0597 %

Dagrente verkopen

-0.0292 %

Valuta

USD

Openingstijden

Markt gesloten

Vrijdag

13:31 - 19:59

Maandag

13:31-19:59

Dinsdag

13:31-19:59

Woensdag

13:31-19:59

Donderdag

13:31-19:59

instr__analysis_statistics

Openen

---

Vorige Sluiten

---

52-weekse hoog/laag

--- – ---

Beurswaarde

131207806976

Uitstaande aandelen

1246630016

Datum winstcijfer (volgende)

2013-01-28

Div. rend.

2025-03-28

Ex-dividenddatum

2025-03-14

Jaarlijks verwachte dividendpercentage

3.16

Jaarlijks verwachte dividendrendement

0.0295

Winst per aandeel

0.38

Meer informatie over dit instrument

Gilead Gilead Sciences Inc
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.

Gerelateerde instrumenten

Activa
Verkoop
Koop
% verandering

Handel nu

Handel nu

Handel nu

Handel nu
Gerelateerde instrumenten
Trustpilot